Published in Nucleic Acids Res on January 13, 2014
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell (2015) 1.77
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A (2014) 1.01
Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer. Proc Natl Acad Sci U S A (2015) 0.96
Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J (2014) 0.92
The GATA factor revolution in hematology. Blood (2017) 0.90
SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res (2014) 0.90
Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat Genet (2016) 0.87
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Res (2016) 0.78
FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene (2016) 0.77
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
GATA factors in endocrine neoplasia. Mol Cell Endocrinol (2015) 0.77
Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Oncotarget (2016) 0.76
An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells. PLoS One (2015) 0.76
A Gata2-Dependent Transcription Network Regulates Uterine Progesterone Responsiveness and Endometrial Function. Cell Rep (2016) 0.75
Role of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Invest (2017) 0.75
Emerging data on androgen receptor splice variants in prostate cancer. Endocr Relat Cancer (2016) 0.75
Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets. Sci Rep (2016) 0.75
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer. PLoS One (2015) 0.75
Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget (2016) 0.75
Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression. PLoS One (2016) 0.75
The essential role of GATA transcription factors in adult murine prostate. Oncotarget (2016) 0.75
Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect (2017) 0.75
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biol (2017) 0.75
GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol (2017) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
Molecular portraits of human breast tumours. Nature (2000) 94.14
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell (2010) 23.97
Mediator and cohesin connect gene expression and chromatin architecture. Nature (2010) 14.34
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell (2002) 8.59
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res (2006) 7.72
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol (2006) 7.11
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet (2011) 6.98
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc (2007) 6.28
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature (2011) 6.10
Pioneer transcription factors: establishing competence for gene expression. Genes Dev (2011) 6.01
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 and FOG-1. Mol Cell (2005) 5.77
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22
GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell (2006) 4.98
Concern Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci U S A (2008) 4.31
Hepatic specification of the gut endoderm in vitro: cell signaling and transcriptional control. Genes Dev (1996) 3.80
Modification of enhancer chromatin: what, how, and why? Mol Cell (2013) 3.62
Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J (2010) 3.25
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism. Cell (2011) 3.00
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res (2007) 2.95
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J (1998) 2.81
Specific glucocorticoid receptor binding to DNA reconstituted in a nucleosome. EMBO J (1988) 2.66
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
GATA transcription factors as potentiators of gut endoderm differentiation. Development (1998) 2.20
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res (2011) 1.89
FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (2010) 1.86
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res (2012) 1.77
Cistromics of hormone-dependent cancer. Endocr Relat Cancer (2009) 1.58
Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate (2005) 1.45
Pioneer factors in hormone-dependent cancers. Nat Rev Cancer (2012) 1.43
FOXA1: master of steroid receptor function in cancer. EMBO J (2011) 1.36
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34
Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J (2011) 1.33
Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol Cell Endocrinol (2011) 1.18
T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation. Cell Rep (2012) 1.16
A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene (2009) 1.15
Functional regulation of GATA-2 by acetylation. J Leukoc Biol (2004) 1.14
FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem Biophys Res Commun (2007) 1.14
Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab (2011) 1.07
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate (2008) 1.05
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis (2006) 0.94
CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2. Nucleic Acids Res (2013) 0.89
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Arch (2013) 0.87
Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res (2012) 0.85
Differential expression and function of AR isoforms in prostate cancer. Oncol Rep (2011) 0.80
Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism. PLoS One (2013) 0.79
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res (2006) 6.75
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature (2010) 6.26
Nucleosome dynamics define transcriptional enhancers. Nat Genet (2010) 5.94
Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol (2007) 5.31
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell (2002) 3.21
ZNF274 recruits the histone methyltransferase SETDB1 to the 3' ends of ZNF genes. PLoS One (2010) 3.15
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res (2007) 2.97
Buonocore Memorial Lecture. Review of the clinical survival of direct and indirect restorations in posterior teeth of the permanent dentition. Oper Dent (2004) 2.90
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet (2011) 2.85
Locating mammalian transcription factor binding sites: a survey of computational and experimental techniques. Genome Res (2006) 2.82
Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging (2013) 2.72
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 2.62
Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci (2005) 2.61
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem (2010) 2.49
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
A repressor complex governs the integration of flowering signals in Arabidopsis. Dev Cell (2008) 2.24
Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol (2011) 2.24
T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem (2006) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res (2007) 2.21
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3. Genome Biol (2012) 2.19
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer (2002) 2.16
Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res (2004) 2.13
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat (2010) 2.12
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites. Genome Res (2008) 2.07
Noninvasive assessment of LV contraction patterns using CMR to identify responders to CRT. JACC Cardiovasc Imaging (2013) 2.06
Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet (2011) 2.05
MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res (2009) 2.03
Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet (2012) 2.00
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res (2007) 1.96
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res (2005) 1.89
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J Biol Chem (2007) 1.88
Alcohol alters DNA methylation patterns and inhibits neural stem cell differentiation. Alcohol Clin Exp Res (2011) 1.88
Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (2006) 1.86
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology (2008) 1.82
Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One (2012) 1.82
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res (2013) 1.81
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78
Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene (2004) 1.77
Genomic targets of the KRAB and SCAN domain-containing zinc finger protein 263. J Biol Chem (2009) 1.71
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology (2005) 1.67
Direct interaction of AGL24 and SOC1 integrates flowering signals in Arabidopsis. Development (2008) 1.66
Wnt5a regulates Shh and Fgf10 signaling during lung development. Dev Biol (2005) 1.66
CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol (2005) 1.66
Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein. Vet Microbiol (2008) 1.66
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One (2011) 1.63
Neuregulin 1 regulates excitability of fast-spiking neurons through Kv1.1 and acts in epilepsy. Nat Neurosci (2011) 1.58
EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res (2011) 1.58
W-ChIPeaks: a comprehensive web application tool for processing ChIP-chip and ChIP-seq data. Bioinformatics (2010) 1.57
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res (2005) 1.56
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther (2006) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Southeast Asian foot-and-mouth disease viruses in Eastern Asia. Emerg Infect Dis (2012) 1.53
Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation. Epigenetics (2009) 1.53
N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res (2008) 1.52
DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination. Biochem Biophys Res Commun (2010) 1.52
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res (2008) 1.52
ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res (2011) 1.52
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res (2004) 1.50